Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2019 Jan 29. doi: 10.1038/s41391-019-0129-2. [Epub ahead of print]

PMID:
30696944
2.

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.

Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378. doi: 10.1038/s41391-017-0031-8. Epub 2017 Dec 22.

PMID:
29273728
3.

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A.

Br J Cancer. 2018 May;118(9):1248-1254. doi: 10.1038/s41416-018-0055-4. Epub 2018 Mar 22.

PMID:
29563633
4.

Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Scand J Urol. 2017 Feb;51(1):5-12. doi: 10.1080/21681805.2016.1271353. Epub 2017 Jan 13.

PMID:
28084175
5.

Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.

Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):66-76. doi: 10.1038/s41391-018-0087-0. Epub 2018 Sep 13.

PMID:
30214034
6.

Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.

Murtola TJ, Vettenranta AM, Talala K, Taari K, Stenman UH, Tammela TLJ, Auvinen A.

Eur Urol Focus. 2018 Dec;4(6):851-857. doi: 10.1016/j.euf.2017.03.005. Epub 2017 Mar 24.

PMID:
28753870
7.

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

Yli-Hemminki TH, Laurila M, Auvinen A, Määttänen L, Huhtala H, Tammela TL, Kujala PM.

BJU Int. 2013 Oct;112(6):735-41. doi: 10.1111/bju.12153. Epub 2013 Jun 7.

8.

Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Sälli SM, Talala K, Taari K, Tammela TLJ, Auvinen A.

Prostate Cancer Prostatic Dis. 2019 Jan 24. doi: 10.1038/s41391-018-0123-0. [Epub ahead of print]

PMID:
30679762
9.

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR.

Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6.

10.

Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.

Joentausta RM, Rannikko A, Murtola TJ.

Prostate. 2019 May;79(6):583-591. doi: 10.1002/pros.23768. Epub 2019 Jan 16.

PMID:
30652328
11.

Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.

Prostate. 2015 Sep;75(13):1394-402. doi: 10.1002/pros.23020. Epub 2015 Jun 12.

PMID:
26073992
12.

Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.

13.

Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Kinnunen PT, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A.

Scand J Urol. 2016 Dec;50(6):413-419. Epub 2016 Sep 14.

PMID:
27628763
14.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

15.

Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.

PMID:
22704366
16.

Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort.

Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A.

Scand J Urol. 2018 Oct - Dec;52(5-6):321-327. doi: 10.1080/21681805.2018.1559882. Epub 2019 Jan 30.

PMID:
30698056
17.

Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial.

Murtola TJ, Tammela TL, Määttänen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A.

Int J Cancer. 2010 Oct 1;127(7):1650-9. doi: 10.1002/ijc.25165.

18.

A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.

Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M.

Eur Urol. 2015 Oct;68(4):591-7. doi: 10.1016/j.eururo.2014.04.005. Epub 2014 Apr 18.

PMID:
24794075
19.

Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Eur Urol. 2014 Jan;65(1):177-85. doi: 10.1016/j.eururo.2012.08.070. Epub 2012 Sep 7.

PMID:
22981136
20.

Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study.

Shih HJ, Kao MC, Tsai PS, Fan YC, Huang CJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):328-333. doi: 10.1038/pcan.2017.14. Epub 2017 Apr 11.

PMID:
28398294

Supplemental Content

Support Center